Cell Medica coalition kicks off Phase II of cellular therapy in CMV
This article was originally published in Scrip
Executive Summary
A coalition including Cell Medica, the UK company focused on cellular immunotherapy products for infectious diseases and cancer, has launched a Phase II clinical trial of adoptive cellular therapy for the pre-emptive treatment of cytomegalovirus (CMV) infections in patients who have received a bone marrow transplant from an unrelated donor.